Severe diarrhoea caused by highly ciprofloxacin-susceptible Campylobacter isolates

Clinical Microbiology and Infection

Volumn 15, Issue 2, 2009, Pages 188-192

  Feodoroff, F Benjamin L ^a   Lauhio, A R ^b   Sarna, S J ^c   Hanninen M L ^c   Rautelin, H I K ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Campylobacter coli; Campylobacter infections; Campylobacter jejuni; Ciprofloxacin; Diarrhoea; Drug resistance; Finland; Fospitalization; Microbial; Signs and symptoms

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CAMPYLOBACTER COLI; CAMPYLOBACTER JEJUNI; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DIARRHEA; FECES ANALYSIS; FEMALE; FEVER; FINLAND; GRAM NEGATIVE INFECTION; HEMATOCHEZIA; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; QUESTIONNAIRE; SALMONELLA TYPHI; VOMITING;

BACTERIA (MICROORGANISMS); CAMPYLOBACTER; CAMPYLOBACTER COLI; CAMPYLOBACTER JEJUNI;

EID: 62149127890     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2008.02657.x     Document Type: Article

References (19)

1. Friedman CR, Neimann J, Wegener HC et al. Epidemiology of Campylobacter jejuni infections in the United States and other industrialized nations. In: Nachamkin I, Blaser MJ, eds, Campylobacter, 2nd edn. Washington: American Society for Microbiology, 2000; 121-138.
2. Rautelin H, Hänninen ML. Campylobacters: The most common bacterial enteropathogens in the Nordic countries. Ann Med 2000; 32: 440-445.
3. Schönberg-Norio D, Takkinen J, Hänninen ML et al. Swimming and Campylobacter infections. Emerg Infect Dis 2004; 10: 1474-1477.
4. Skirrow MB, Blaser MJ. Clinical aspects of Campylobacter infection. In: Nachamkin I, Blaser MJ, eds, Campylobacter, 2nd edn. Washington: American Society for Microbiology, 2000; 69-88.
5. Gillespie IA, O'Brien SJ, Frost JA et al. Investigating vomiting and/or bloody diarrhoea in Campylobacter jejuni infection. J Med Microbiol 2006; 55: 741-746.
6. Ternhag A, Asikainen T, Giesecke J et al. A meta-analysis on the effects of antibiotic treatment on duration of symptoms caused by infection with Campylobacter species. Clin Infect Dis 2007; 44: 696-700.
7. Endtz HP, Ruijs GJ, van Klingeren B et al. Quinolone resistance in Campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. J Antimicrob Chemother 1991; 27: 199-208.
8. Rautelin H, Renkonen OV, Kosunen TU. Emergence of fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli in subjects from Finland. Antimicrob Agents Chemother 1991; 35: 2065-2069.
9. Engberg J, Aarestrup FM, Taylor DE et al. Quinolone and macrolide resistance in Campylobacter jejuni and C..coli: Resistance mechanisms and trends in human isolates. Emerg Infect Dis 2001; 7: 24-34.
10. Gupta A, Nelson JM, Barrett TJ et al. Antimicrobial resistance among Campylobacter strains in the United States, 1997-2001: Increasing prevalence of ciprofloxacin resistance. Emerg Infect Dis 2004; 10: 1102-1109.
11. Campylobacter Sentinel Surveillance Scheme Collaborators. Ciprofloxacin resistance in Campylobacter jejuni: Case-case analysis as a tool for elucidating risks at home and abroad. J Antimicrob Chemother 2002; 50: 561-568.
12. Nelson JM, Smith KE, Vugia DJ et al. Prolonged diarrhea due to ciprofloxacin-resistant Campylobacter infection. J Infect Dis 2004; 190: 1150-1157.
13. Engberg J, Neimann J, Nielsen EM et al. Quinolone-resistant Campylobacter infections: Risk factors and clinical consequences. Emerg Infect Dis 2004; 10: 1056-1063.
14. Helms M, Simonsen J, Olsen KE et al. Adverse health events associated with antimicrobial drug resistance in Campylobacter species: A registry-based cohort study. J Infect Dis 2005; 191: 1050-1055.
15. Unicomb LE, Ferguson J, Stafford RJ et al. Low-level fluoroquinolone resistance among Campylobacter jejuni isolates in Australia. Clin Infect Dis 2006; 42: 1368-1374.
16. Wassenaar TM, Kist M, de Jong A. Re-analysis of the risks attributed to ciprofloxacin-resistant Campylobacter jejuni infections. Int J Antimicrob Agents 2007; 30: 195-201.
17. Clinical and Laboratory Standards Institute/NCCLS. Performance for antimicrobial susceptibility testing; fifteenth informational supplement. CLSI/NCCLS document M100-S15. Wayne, PA: CLSI, 2005.
18. Clinical and Laboratory Standards Institute. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guideline. CLSI document M45-A. Wayne, PA: CLSI, 2006.
19. Ternhag A, Törner A, Svensson A et al. Mortality following Campylobacter infection: A registry-based linkage study. BMC Infect Dis 2005; 5: 70.